abstract |
The present invention relates to novel imidazopyridine derivatives having good affinity for certain subtypes of the melanocortin receptor, in particular the MC4 receptor. These derivatives are particularly useful for treating pathological conditions and diseases involving one or more melanocortin receptors. The present invention also relates to pharmaceutical compositions containing the aforementioned compounds. |